Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Cancer Research UK · Royal Marsden Hospital · +24 more institutions
Abstract
AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor–positive advanced breast cancer are limited. Download a PDF of the Research Summary. In a phase 3, randomized, double-blind trial, we enrolled eligible pre-, peri-, and postmenopausal women and men with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer who had had a relapse or disease progression during or after treatment with an aromatase inhibitor, with or without previous cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy. Patients were…
Citation impact
- FWCI
- 165.20
- Percentile
- 100%
- References
- 35
Authors
23- NCNicholas C. TurnerCorresponding
Cancer Research UK, Royal Marsden Hospital
- MOMafalda Oliveira
Hebron University, Cancer Research UK, Vall d'Hebron Institute of Oncology
- SJSacha J. Howell
Cancer Research UK, The Christie NHS Foundation Trust
- FDFlorence Dalenc
Cancer Research UK, Institut Claudius Regaud
- JCJavier Cortés
Cancer Research UK, MedSIR (Spain), Universidad Europea de Madrid
Topics & keywords
- Fulvestrant
- Breast cancer
- Medicine
- Hormone receptor
- Internal medicine
- Hormone
- Endocrine system
- Oncology
- Good health and well-being